

### **REMARKS**

Claims 1 to 10 were under consideration. The Action stated that the claims in Groups I to IV covered distinct inventions, and specifically provided reasons as follows:

#1- Inventions I and II were unrelated

#2- Inventions I and III were unrelated

#3- Inventions II and III were unrelated

#4- Inventions II and IV were related as product and process of use

#6- Inventions I and IV were unrelated

#7- Inventions III and IV were unrelated

In response, applicant traverses on the grounds that the inventions are not patentably distinct, but in the interest of moving the prosecution forward, applicant elects to prosecute claims in Group I, i.e., claims 1, 2, 7 and 8 drawn to the composition of an EEIIMI polypeptide and a fibrinolytic agent and method of enhancing the fibrinolytic activity of said agent, classified in class 424, subclass 94.64. Claims 9 and 10 are amended in preparation for rejoinder with product claims. Applicant withdraws the remaining claims 3, 4, 5, and 6.

### ***Election of Species***

The Action states that Claims 2, 4, 6, 8 and 10 are generic to the plurality of disclosed patentably distinct species comprising at least fifteen fibrinolytic agents,

and requires the applicant to elect a single disclosed species under U.S.C. 121. Applicant traverses this requirement, but for the purpose of moving the prosecution forward, applicant elects the species scuPA.

### ***Notice of Entitlement to Rejoinder of Process Claims***

The Action states that where applicant elects claims directed to a product, and a product claim is subsequently found allowable, withdrawn process claims that depend from allowable product claim will be rejoined under MPEP 821.04. Applicant is advised to amend the process claims.

The process claims in the present application are listed as claims 9 and 10 in Group IV. Therefore, in accordance with the above guidance, applicant has submitted amended process claims, which are submitted for consideration for rejoinder with product claims 1 and 2, in the event claims 1 and 2 are allowed. Accordingly, amended claims 9 and 10 have been submitted herewith.


### ***Sequence Disclosure Compliance Notice***

In accordance with the requirement of 37 C.F.R. 1.821(a)(1) and (a) 2), applicant has submitted herewith a copy of the disk with attached paper copy of the Sequence Listing in accordance with 37 C.F.R. 1.181( c ), within ONE MONTH of the mailing of the Office Action.

Applicant has made diligent effort to amend the claims and respond to points made in the Office Action. If for any reasons however, the Examiner should deem that this application is not in condition for allowance, the Examiner is respectfully requested to telephone the undersigned attorney listed below to resolve any

outstanding issues prior to issuing a further Office Action.

Respectfully submitted,



Rashida A. Karmali, Esq.

Reg. No. 43,705

Attorney for Applicants

99 Wall Street, 13th Floor

New York, New York 10005

212-651-9653

Date: September 21, 2004